A recent study by Nishimoto et al showcased the adaptation of these engineering approaches to Vδ1 γδ T cells (ADI-270) by coexpressing a CD70-targeted CAR and a dominant-negative TGFβRII receptor (dnTGFβRII) to target CD70+ malignancies, addressing immunosuppression and host-versus-graft rejection. This commentary explores αβ T cell-derived engineering strategies applicable to γδ T cells, while also highlighting genome-editing innovations poised to advance next-generation γδ CAR-T development.

27 days ago

Journal

CD70 (CD70 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)

2ms

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)

P1/2, N=19, Completed, CRISPR Therapeutics AG | Recruiting --> Completed | N=250 --> 19 | Trial completion date: May 2030 --> Sep 2025 | Trial primary completion date: Apr 2030 --> Sep 2025

2 months ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

CTX131

3ms

Universal CAR-T Cell Therapy for Cancer Treatment: Advances and Challenges. (PubMed, Oncol Res)

Although trials for solid tumors (e.g., CYAD-101, CTX130) show modest responses, challenges such as tumor heterogeneity and T cell exhaustion remain. Future research should focus on optimizing gene editing precision, integrating combination therapies, and advancing scalable manufacturing platforms. With expanded targets and cell types, UCAR therapies show promise for both hematologic and solid tumors, reshaping cancer treatment and patient outcomes.

3 months ago

Review • Journal

CD52 (CD52 Molecule)

CYAD-101 • CTX130

4ms

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus (clinicaltrials.gov)

P1, N=15, Recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

4ms

CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions. (PubMed, Transl Oncol)

CD70, as a surface antigen expressed on tumor cells in a variety of hematologic malignancies, including acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, etc., and solid tumors such as renal cell carcinoma, osteosarcoma, and glioma, is a potential target for CAR-T/NK cells. Several preclinical studies and clinical trials on CAR-T/NK cells targeting CD70 are currently underway, bringing new hope for the treatment of CD70-positive tumors.

4 months ago

Review • Journal

CD70 (CD70 Molecule)

4ms

TRAVERSE: Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)

P1, N=120, Active, not recruiting, Allogene Therapeutics | Recruiting --> Active, not recruiting

4 months ago

Enrollment closed

cyclophosphamide • fludarabine IV • ALLO-316 • ALLO-647

4ms

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases (clinicaltrials.gov)

P1, N=11, Recruiting, Chongqing Precision Biotech Co., Ltd